Discusses the challenges faced in biotechnology dosage form development

Provides practical and applied guidance in many areas including stability, microbiology and manufacturing, as well as case studies in life-cycle management

Includes comprehensive information on the use of polysorbate exipients in formulation

Discusses the challenges faced in biotechnology dosage form development Provides practical and applied guidance in many areas including stability, microbiology and manufacturing, as well as case studies in life-cycle management Includes comprehensive information on the use of polysorbate exipients in formulation

Autorentext

Nicholas W. Warne is currently Senior Director of Formulations and Drug Product Process Development at Pfizer. Dr. Warne has 28 years of industrial experience focusing on biologics formulation development, dosage form design and manufacturing process development. He and his team have been fortunate to have contributed to the licensure of 10 biologics including clotting factors, growth proteins, mabs, vaccines and ADCs. Dr. Warne holds numerous protein formulation patents and, with his group, has made over 100 presentations at national meetings and in journals. Prior to his position at Pfizer, Dr. Warne had positions of increasing responsibility at Wyeth and Genetics Institute, and has been based in Andover, Massachusetts.

Dr. Warne received his PhD in Chemistry from Purdue University under the guidance of Professor Michael Laskowski Jr. He received his BS in Biochemistry, with Distinction in Research, from the University of Rochester.

Hanns-Christian Mahler. Since September 2015, Dr. Mahler is leading the Drug Product services organization at Lonza AG, a leading service provider for the Pharma and Biotech industry. Prior this position, he led the department Pharmaceutical Development & Supplies, Biologics EU at Roche, Basel, Switzerland from 2010 to 2015 and as Head of Formulation R&D Biologics, Roche, Basel, from 2005 to 2010. From 2000-2005, Dr. Mahler was working at Merck KGaA, Darmstadt, Germany as Principal Formulation Scientist, Lab Manager for Protein Formulation Development and Clinical Trial Manufacturing and CMC Team leader for Erbitux during its submission and launch phase.

Dr. Mahler studied Pharmacy at the University of Mainz, Germany, holds in Ph.D. in Toxicology from the Institute of Pharmacy, University of Mainz and Pharmacist specialization degrees in Toxicology & Ecology and Pharmaceutical Technology. He was further trained in Economy and Marketing. Dr. Mahler obtained his venia legendi (german Habilitation) from the University of Frankfurt/Germany in 2010 and is adjunct faculty and lecturer at the universities of Frankfurt (Germany), and Basel (Switzerland). He was elected an AAPS Fellow in November 2013, nominated extraordinary Professor for Pharmaceutical Technology in November 2015 and received the PDA Distinguished Service Award in 2018.

Zusammenfassung

Discusses the challenges faced in biotechnology dosage form development

Provides practical and applied guidance in many areas including stability, microbiology and manufacturing, as well as case studies in life-cycle management

Includes comprehensive information on the use of polysorbate exipients in formulation

Inhalt
Part 1. Formulation Development of Biologics.- Introduction into Formulation Development of Biologics.- Part 2. Challenges with Excipients.- Polysorbate Degradation and Quality.- Sucrose and Trehalose in Therapeutic Protein Formulations.- Part 3. High Concentration Proteins.- Introduction to High-Concentration Proteins.- Solubility, Opalescence & Particulate Matter.- Analytical Characterization and Predictive Tools for Highly Concentrated Protein Formulations.- Practical Considerations for High Concentration Protein Formulations.- Part 4. Container-Closure Systems.- Parenteral Container Closure Systems.- Development of Prefilled Syringe Combination Products for Biologics.- Special Topics in Analytics of Pre-filled Syringes.- C Mini-Pumps.- Container Closure Integrity Testing of Primary Containers for Parenteral Products.- Chemical Durability of Glass Delamination.- Part 5. Processing Considerations.- Bulk Protein Solution: Freeze Thaw Process, Storage and Shipping Considerations.- Leachables and Extractables: From Regulatory Expectations to Laboratory Assessment.- Biotherapeutic Drug Product Manufacturing and Process Development.- Line Sterilization Considerations and VHP.- Lyophilization: Process Design, Robustness and Risk Management.- Fogging.- Scientific Approaches for the Application of QbD Principles in Lyophilization Process Development.- Manufacturing of Highly Potent Drug Product in a Clinical Multi-Product Aseptic Facility and Transfer of Principles to Antibiotic Drug Product.- Part 6. Novel Constructs.- Introduction into Novel Constructs.- Novel Constructs Half-Life Extensions.- Fc Fusion Proteins.- Part 7. Lifecycle Management.- Lifecycle Management of Biotherapeutic Dosage Forms.- Switching from an IV to an SC Formulation Considerations for Formulation Development and Formulation Bridging.